NZJeMA Jewish Medicine Pulse

Jewish Medicine Pulse #2 — 15 September 2026

Mon, 14 Sep 2026 21:00:00 +0000

Editorial digest only; not medical advice.

New Zealand funds flu vaccination for every child under five as cases rise
From 1 September 2026 the influenza vaccine is fully funded for every child from six months to their fifth birthday. Pharmac and Health NZ made the change in response to a late-season surge in which under-fives showed the highest influenza-related hospitalisation rates of any age group. Pharmac says national stock is sufficient, and Health NZ is working with general practice, pharmacies and Māori and Pacific providers on immediate access.
Why it matters: Clinicians can offer the vaccine at no cost to families straight away, removing a cost barrier for the group most likely to be admitted.
Caveat: A funding decision, not a new efficacy finding. Uptake still depends on access and awareness, and late-season vaccination protects for the remainder of this season only.
Read at Health New Zealand | Te Whatu Ora + Pharmac

Medsafe approves two psychiatrists to prescribe MDMA-assisted therapy for PTSD
Medsafe has authorised two psychiatrists, in Wellington and Auckland, to prescribe pharmaceutical-grade MDMA as part of supervised psychotherapy for eligible adults with post-traumatic stress disorder. Sessions take place in a controlled clinical setting; patients are not supplied MDMA to take home. New Zealand becomes the second country, after Australia in 2023, to permit this.
Why it matters: A substantive step for trauma care in New Zealand, and directly relevant to psychiatrists and GPs fielding patient questions about eligibility and referral.
Caveat: This is not approval of MDMA as a medicine. Use is limited to the two named psychiatrists under specific conditions. The Ministry itself notes the international evidence base is still emerging, and the US FDA declined a similar application in 2024 over trial-design concerns.
Read at New Zealand Ministry of Health

Māori Health Strategy 2026 – Whiria te Ora sets a five-year direction
Whiria te Ora consolidates previous Māori health strategies into a single delivery-focused framework for the next five years, built on two outcomes: a fair, safe and sustainable system delivering equal outcomes for Māori, and whānau, hapū, iwi and communities exercising authority over their own wellbeing. It was shaped through engagement with the Hauora Māori Advisory Committee, iwi-Māori Partnership Boards and Māori providers.
Why it matters: It is the framework every Health NZ service and provider will be measured against for Māori health, and a useful reference point for a small professional network thinking about its own equity commitments.
Caveat: A direction-setting document. It does not by itself change funding, workforce or service delivery, and its outcome measures will only be testable over years.
Read at New Zealand Ministry of Health

Mental Health and Wellbeing Strategy 2026–2036 launched with a three-year implementation plan
Launched at Parliament on 6 August 2026 alongside its first implementation plan covering 2026/27 to 2028/29, the ten-year strategy sets the direction for mental health, addiction and wellbeing services. Around 900 people and organisations contributed through public consultation, which sharpened its focus on wider determinants of wellbeing, diverse communities, lived-experience leadership and measurable accountability.
Why it matters: It sits alongside the new Mental Health Act 2026, which received Royal Assent on 9 July and commences in July 2028—together they reset the legal and strategic frame for mental health practice in New Zealand.
Caveat: Strategies describe intent; the implementation plan's milestones and reporting are what to watch. Nothing here changes clinical practice on its own.
Read at New Zealand Ministry of Health

Healthy Futures (Pae Ora) Amendment Act 2026 adds ‘timely access to quality services’ as a statutory purpose
Signed into law on 9 July 2026, the Amendment Act changes the purpose, objectives and functions of Health New Zealand, increases its focus on infrastructure, strengthens the Hauora Māori Advisory Committee and clarifies iwi-Māori Partnership Boards, and adds a new statutory purpose: ensuring patients get timely access to quality services.
Why it matters: A change to the statutory mandate of the organisation most clinicians in New Zealand work for or with, and the legal hook for the Government's health targets.
Caveat: Legal purpose is not delivery. The practical effect on waiting times and access will depend on funding, workforce and how Health NZ's board interprets the new duty.
Read at New Zealand Ministry of Health

Australian royal commission hears Jewish patients ask ‘Am I safe going to the hospital?’
At the Royal Commission on Antisemitism and Social Cohesion, gastroenterologist Adam Gordon and dermatologist Jack Green of the Australasian Jewish Medical Federation gave evidence that Jewish and Israeli patients had lost trust in the health system, with some asking whether they were safe going to hospital. Both recommended prohibiting staff from wearing political symbols in clinical settings. South Western Sydney Local Health District said its staff must comply with political-neutrality codes and it had introduced uniform policies barring politically or religiously contentious clothing and accessories.
Why it matters: The witnesses are NZJeMA's Australian counterpart. The questions raised—patient trust, professional neutrality, what belongs in a clinical space—are the same ones New Zealand health employers and regulators will face.
Caveat: Testimony, not findings. The Commission has not reported. Use allegation language for any specific incident, and note that policies on symbols are contested within the profession.
Read at ABC News

AHPRA adopts the IHRA definition of antisemitism—and draws organised pushback
In a 17 June joint statement with Australia's Special Envoy to Combat Antisemitism, AHPRA adopted the International Holocaust Remembrance Alliance definition, with the Envoy's handbook, as a reference tool for its regulatory work. Nearly 2,000 practitioners signed an open letter warning it could target lawful advocacy, and civil-liberties bodies argued it would chill criticism of Israel; AHPRA's chief executive has acknowledged the free-speech concerns.
Why it matters: The first health regulator in the region to adopt a working definition of antisemitism. New Zealand's Medical Council and responsible authorities will be asked whether they intend to follow, and the arguments on both sides are now on the record.
Caveat: This item is deliberately balanced: the adoption is real and so is the opposition. AHPRA describes it as a reference tool, not a new ground for complaint. Three months old, included because Issue #1 did not cover it and it remains live.
Read at Australian Health Practitioner Regulation Agency + AusDoc

Investigation: more than 30 Australian health professionals describe antisemitism at work and on the wards
An investigation by The Australian, written by Megan Goldin and based on interviews with more than 30 doctors, nurses, midwives and other health workers, reports allegations that antisemitism has intensified in Australian healthcare since October 2023. Alleged incidents include Jewish patients concealing their identity, repeated painful cannulation attempts, withheld analgesia, Holocaust-denial remarks by staff, and anti-Israel stickers placed in clinical areas including near a dying patient's bed. Interviewees criticised AHPRA's response.
Why it matters: The most detailed account yet of what Jewish patients and clinicians say they are experiencing in a health system very like New Zealand's, and the context for the royal commission hearings above.
Caveat: Allegations reported by a newspaper, not adjudicated findings; the original article is paywalled and this item relies on secondary reporting. Individual incidents have not been independently verified. Use allegation language throughout.
Read at The Australian, via ynetnews and JNS

Human Atlas: a free, open-source 3D anatomy explorer with 2,234 selectable structures
A browser-based anatomy explorer that takes the BodyParts3D adult male reference model apart into 2,234 individually selectable meshes across 15 body systems, with search, system layering, and an exploded layer-by-layer view. It runs in a browser with no account or API key, and the code is open source. The underlying meshes come from BodyParts3D, a CC BY 4.0 dataset from Japan's Database Center for Life Science.
Why it matters: NZJeMA now hosts its own copy, so members, students and trainees have a stable link that does not depend on a third-party demo staying up. A free, offline-capable teaching aid that asks nothing of the user.
Caveat: The repository itself states it is an educational explorer, not a diagnostic or surgical tool. It represents male anatomy only, because no free female dataset exists at this level of detail. Mesh accuracy is that of the 2009 BodyParts3D reference, not a clinical model.
Read at Hosted by NZJeMA · code by ashemag (MIT) · data BodyParts3D (CC BY 4.0)

Jewish Medicine Pulse #1 — 15 August 2026

Fri, 14 Aug 2026 21:00:00 +0000

Editorial digest only; not medical advice.

New Zealand backs a national pre-implementation framework for health AI
Health NZ says its Board endorsed a national framework for evaluating health AI for safety, security, ethics and equity before deployment. The tool was HRC-funded, co-designed and pre-tested.
Why it matters: It is directly relevant to New Zealand clinicians and technology leaders deciding how AI should be assessed before it reaches patients.
Caveat: Endorsing an evaluation framework does not validate any AI product or prove that future implementations will be safe or effective; the development paper was still under peer review when announced.
Read at Health New Zealand | Te Whatu Ora

New Zealand publishes its 2026/27 Rare Disorders Strategy implementation plan
The plan brings together the Ministry, Health NZ, Pharmac, HQSC and Rare Disorders NZ. Actions include a clinical expert group, continued genome-sequencing pilot work, better data and clinical information, and review of exceptional-circumstances medicine access.
Why it matters: It connects New Zealand diagnostic genomics with service coordination and access to treatment—an area where small professional networks can help patients navigate fragmented care.
Caveat: This is a commitment and work programme, not evidence that the promised improvements or patient outcomes have already been delivered.
Read at New Zealand Ministry of Health

Israeli team reports a lower-cost, sequencing-free blood test approach for lung cancer
A Tel Aviv University-led team describes a fluorescence and microarray assay that profiles cfDNA methylation without sequencing. In the 60-person blinded test set within a 103-person stage II–IV lung-cancer-versus-healthy-control study, it reported 93.1% sensitivity and 90.3% specificity.
Why it matters: The approach aims to reduce cost and laboratory complexity, making it an interesting Israeli translational-science story with a potential access benefit.
Caveat: This is not ready for routine screening. Healthy controls can make specificity look better than it would in a real symptomatic or screening population; stage I performance is unproven, the cohort was small, and the assay does not replace low-dose CT. Larger prospective studies are needed.
Read at ynet Health + npj Precision Oncology

A molecular ‘cloak’ gets full-size antibodies inside cells in preclinical models
Researchers from Tel Aviv University, the Technion and Cornell used a reversible SL4 molecular coating to package full-length antibodies in organ-targeted lipid nanoparticles. The team tested intracellular delivery in neuronal cultures and an acute-lung-injury mouse model.
Why it matters: Full antibodies usually cannot cross cell membranes. A reversible delivery method could eventually widen the range of intracellular targets available to biologic medicines.
Caveat: This is early preclinical platform science—not a Parkinson’s, cancer or inflammatory-disease treatment. Human safety, dose, tissue targeting and clinical efficacy remain unknown.
Read at ynet Health + PNAS

Update: Australian appeal court restores the Bankstown nurses video as trial evidence
A New South Wales appeal court overturned the June evidentiary ruling, allowing the unedited recording to be used at the former nurses’ forthcoming trials. Both defendants deny the charges; admitting the video does not determine guilt.
Why it matters: The case sits directly at the intersection of antisemitism, professional conduct and Jewish patients’ trust in healthcare, with obvious relevance across the Australasian health workforce.
Caveat: Use allegation language throughout. Australian authorities previously said they had found no evidence that any patient was harmed. The reader-supplied June ynet report is now superseded: Max Veifer gave evidence by video link from Israel, and earlier reporting said travel was planned only if he was later required in person.
Read at Australian court reporting + NSW Supreme Court listing

Early-life sugar rationing is linked to lower later-life dementia risk—but does not prove causation
Among 60,394 UK Biobank participants, exposure to wartime sugar rationing during the first 1,000 days of life was associated with lower later-life rates of dementia, Alzheimer’s disease, depression and anxiety.
Why it matters: The 46% Alzheimer’s headline is highly shareable; this is a useful example of translating a striking association without overstating what the study can establish.
Caveat: This was not a randomised trial and individual sugar intake was not measured. Historical confounding and UK Biobank selection remain possible, so the result should not create new clinical advice on its own.
Read at ynet Health + npj Aging

Therapy dogs increased engagement; this small trial did not detect better discharge outcomes
In a 50-patient inpatient stroke-rehabilitation study, sessions involving certified therapy dogs increased therapist-rated engagement, movement and time standing. The two groups nevertheless had similar recovery, quality-of-life, anxiety and self-care outcomes at discharge.
Why it matters: It is an appealing positive story whose most important nuance is the difference between better participation during therapy and better clinical outcomes.
Caveat: The trial was small, single-centre and short. Greater engagement did not translate into superior final recovery; larger and longer studies are needed.
Read at ynet Health + Mayo Clinic Proceedings

Imaging-selected clot-busting treatment can help some patients beyond 4.5 hours
A meta-analysis found that carefully imaging-selected patients treated at least 4.5 hours after ischaemic stroke onset had better 90-day functional outcomes, alongside a higher risk of symptomatic intracerebral haemorrhage and no significant mortality difference.
Why it matters: This helps explain why some wake-up and late-presenting stroke patients may still be treatment candidates when advanced imaging shows salvageable brain tissue.
Caveat: The result does not mean the 4.5-hour window or urgency no longer matters. Eligibility is specialist- and imaging-dependent; suspected stroke still requires immediate emergency assessment.
Read at ynet Health + JAMA Network Open

The hardest bone X-rays exposed a large confidence–accuracy gap
In a controlled bone-X-ray task, clinician confidence became poorly calibrated on the hardest cases. Radiologists were more accurate and less overconfident overall than clinicians outside radiology.
Why it matters: Confidence is not the same as correctness. The finding is relevant to diagnostic safety, second-opinion design and how AI support should communicate uncertainty.
Caveat: The widely shared 37% accuracy figure applies only to the hardest experimental cases—not routine radiology error rates. The task lacked full clinical context and used a modest clinician sample.
Read at ynet Health + Radiology

West Nile virus-positive mosquitoes detected in several Israeli locations
ynet reported 13 diagnosed people in Israel’s current West Nile season, including one death, and virus-positive mosquitoes in the Menashe Regional Council, Ramat HaSharon and Eilat. The figures were attributed to the health and environment ministries.
Why it matters: It is a timely One Health story for clinicians, travellers and families with connections to Israel, and it demonstrates why surveillance cards need a visible checking date.
Caveat: Case counts and affected locations can change quickly. Most infections are asymptomatic, but severe neurological disease can occur; any external issue should replace these numbers with the latest official guidance.
Read at ynet Health citing Israeli health and environment ministries